US-based wound care firm BioMonde has launched its patented biosurgical medical device, BioBag, in the US.
The debridement product for patient use is currently available for clinicians across all 50 US states, DC and Puerto Rico.
BioBag uses all the benefits of biosurgery in an easy-to-use contained dressing and was developed for the debridement of various wounds, including pressure ulcers, neuropathic ulcers, venous stasis ulcers and non-healing traumatic or surgical wounds.
The company said BioBag is currently the only FDA cleared contained biosurgical dressing on the market.
BioMonde product manager Katy Nicell said: "Many of the debridement options currently available do not actively, and selectively, remove bacterial burden and all devitalised tissue from a wound. Biosurgery is unique.
"The wound size does not increase past the level of damaged tissue and nothing unviable is left behind meaning that effective proliferation can take place."
BioBag allows clinicians to debride wounds with precision, while ensuring containment and patient acceptance.
BioMonde CEO Gareth Kempson said: "Historically, bio-surgery was reserved for the most challenging wounds that were not responding to conventional treatment.
"In Europe and the UK, we have proven that the early inclusion of BioBag into the routine debridement practice of non-healing wounds, enables rapid results to be achieved in a cost-efficient manner."
BioMonde manufactured and supplied Larval Therapy in Europe and the UK. The company’s manufacturing facilities are in Bridgend, Wales, Hamburg, Germany and Gainesville, Florida.
Image: BioMonde has launched its patented biosurgical medical device BioBag. Photo: courtesy of Business Wire.